research Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
Search
for
Sort by
Research
150-180 / 1000+ results 
research 173 Impact of Clinical Severity on Absenteeism and Presenteeism in Patients with Hidradenitis Suppurativa
Severe Hidradenitis Suppurativa increases missed and unproductive workdays.
research SP0227 Case 1 Presentation: Arthritis, Lupus and More. Rhupus or Polyautoimmunity?
Managing multiple autoimmune diseases in one patient is very challenging.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research STRIAA (Severity TRichoscopy Index Alopecia Areata): Validation of a Novel Trichoscopic Tool for Evaluation of Alopecia Areata
The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
research SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
research An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Approach to Patients with Suspected Rheumatic Disease
Doctors should use a detailed patient history and physical exam to diagnose joint pain, and consult a rheumatologist early for suspected autoimmune diseases.
research Immune signatures of psoriasis: Comparison of genetic expression profiles in psoriasis patients after therapy with biologic agents
Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.
research EPH225 Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity Among Adults in Taiwan
A comprehensive approach is needed to accurately assess alopecia areata severity and guide treatment decisions.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross‐sectional cohort study
Alopecia areata greatly affects the quality of life for children and their families.
research Th1/Th2 PB balance and CD200 expression of patients with active severe alopecia areata
Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Prevalence of depression and anxiety and their association with disease activity in patients with systemic lupus erythematosus: A cross-sectional study
Depression and anxiety are common in SLE patients and worsen disease symptoms.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
research withdrawn
AGA patients have a lower quality of life than AA patients.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Patient experience in systemic lupus erythematosus: development of novel patient-reported symptom and patient-reported impact measures
New tools were created to help lupus patients report their symptoms and impacts more accurately.